 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...108109110111112113114115116117118...132133» |
- | Signifor (pasireotide) / Recordati
Trial termination, Trial primary completion date: Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=64, Terminated, Sponsor: Thomas Jefferson University
Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Jun 2012; Slow accrual
- cisplatin / Generic mfg., everolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - Jul 15, 2015
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Jun 2012; Slow accrual Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Phase classification, Enrollment change, IO biomarker: Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 14, 2015
P1, N=33, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting Phase classification: P2 --> P1 | N=53 --> 33
- letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Jul 14, 2015
P2, N=72, Recruiting, Sponsor: Gynecologic Oncology Group
Phase classification: P2 --> P1 | N=53 --> 33 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial initiation date: EVINEC: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (clinicaltrials.gov) - Jul 13, 2015
P2, N=40, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Initiation date: Apr 2015 --> Jul 2015
- everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jul 13, 2015
P2, N=53, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: Apr 2015 --> Jul 2015 N=73 --> 53
- everolimus / Generic mfg., azathioprine / Generic mfg.
New P4 trial: Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study (clinicaltrials.gov) - Jul 9, 2015
P4, N=50, Recruiting, Sponsor: Instituto de Urologia e Nefrologia
- everolimus / Generic mfg.
Trial completion, Enrollment change: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) - Jul 9, 2015
P2, N=11, Completed, Sponsor: New York University School of Medicine
N=73 --> 53 Active, not recruiting --> Completed | N=25 --> 11
- everolimus / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients (clinicaltrials.gov) - Jul 8, 2015
P4, N=70, Recruiting, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed | N=25 --> 11 Trial primary completion date: Dec 2014 --> Dec 2016
- |||| everolimus / Generic mfg.
Enrollment open, Metastases: Desiree: Dose EScalation Induction of EvERolimus (clinicaltrials.gov) - Jul 8, 2015
P2, N=156, Recruiting, Sponsor: German Breast Group
Trial primary completion date: Dec 2014 --> Dec 2016 Not yet recruiting --> Recruiting
- everolimus / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: 4EVER UK: An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis (clinicaltrials.gov) - Jul 6, 2015
P4, N=50, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Dec 2015
- apitolisib (GDC-0980) / Roche
Trial completion, Metastases: Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy (clinicaltrials.gov) - Jul 2, 2015
P2, N=85, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Jun 2015 --> Dec 2015 Active, not recruiting --> Completed
- ||||||| everolimus / Generic mfg.
Trial completion, Metastases: RADIANT-3: Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Jul 1, 2015
P3, N=410, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial primary completion date: ELATE: Everolimus and LongActing Octreotide Trial in Polycystic Livers (clinicaltrials.gov) - Jun 29, 2015
P2, N=44, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Jul 2012
- everolimus / Generic mfg., sirolimus / Generic mfg.
New trial: Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=70, Not yet recruiting, Sponsor: Ege University
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jun 26, 2015
P1, N=12, Recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Jul 2012 Not yet recruiting --> Recruiting
- ||| Farydak (panobinostat) / Secura Bio
Enrollment closed, Combination therapy, Epigenetic controller: Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=148, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Trial completion, Enrollment change: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (clinicaltrials.gov) - Jun 25, 2015
P4, N=9, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed | N=20 --> 9
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial initiation date, Combination therapy: Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Jun 25, 2015
P1, N=26, Not yet recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | N=20 --> 9 Initiation date: Dec 2014 --> Sep 2015
- | temozolomide / Generic mfg., everolimus / Generic mfg.
Trial initiation date, Trial primary completion date, Metastases: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) (clinicaltrials.gov) - Jun 25, 2015
P2, N=40, Recruiting, Sponsor: Haukeland University Hospital
Initiation date: Dec 2014 --> Sep 2015 Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2017 --> Dec 2017
- prednisone / Generic mfg., everolimus / Generic mfg.
New P2 trial, Metastases: PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI (clinicaltrials.gov) - Jun 24, 2015
P2, N=42, Not yet recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- ||| Sutent (sunitinib) / Pfizer
Enrollment open, Real-world evidence, Real-world, Metastases: OPALINE : A Study Of Morbidity And Mortality At 2 Years (clinicaltrials.gov) - Jun 24, 2015
P=N/A, N=170, Recruiting, Sponsor: Pfizer
Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Enrollment change, Trial termination: Everolimus on CKD Progression in ADPKD Patients (clinicaltrials.gov) - Jun 23, 2015
P2/3, N=71, Terminated, Sponsor: A. Manzoni Hospital
Not yet recruiting --> Recruiting N=90 --> 71 | Recruiting --> Terminated; After primary completition date, experimental drug was no longer available
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Jun 23, 2015
P2, N=80, Active, not recruiting, Sponsor: University of Chicago
N=90 --> 71 | Recruiting --> Terminated; After primary completition date, experimental drug was no longer available Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| everolimus / Generic mfg.
Enrollment closed: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Jun 18, 2015
P3, N=326, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Trial primary completion date: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jun 17, 2015
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2014 --> Jul 2016
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Jun 17, 2015
P2, N=38, Completed, Sponsor: Italian Sarcoma Group
Trial primary completion date: Jul 2014 --> Jul 2016 Trial primary completion date: Mar 2014 --> Dec 2014
- || everolimus / Generic mfg., sirolimus / Generic mfg.
Enrollment closed, Adverse events, Combination therapy: Comparing Everolimus and Sirolimus in Renal Transplant Recipients (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=60, Active, not recruiting, Sponsor: Dr.Ronald Pelletier
Trial primary completion date: Mar 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- || prednisone / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: PredEver first: Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (clinicaltrials.gov) - Jun 11, 2015
P2a, N=60, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jan 2016
- || Trial primary completion date, Gene Expression Profile, IO biomarker, Biopsy, Post-transplantation: Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=88, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Mar 2015 --> Jan 2016 Trial primary completion date: Apr 2015 --> May 2016
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=185, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2015 --> May 2016 Trial primary completion date: May 2016 --> Nov 2016
- Sutent (sunitinib) / Pfizer
Trial primary completion date, IO biomarker: Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=120, Recruiting, Sponsor: VU University Medical Center
Trial primary completion date: May 2016 --> Nov 2016 Trial primary completion date: Oct 2014 --> Oct 2016
- || everolimus / Generic mfg.
Trial primary completion date: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children (clinicaltrials.gov) - Jun 11, 2015
P2, N=65, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Oct 2014 --> Oct 2016 Trial primary completion date: Nov 2014 --> Nov 2015
- istiratumab (MM-141) / Ipsen
Trial primary completion date, Metastases: A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 11, 2015
P1, N=45, Recruiting, Sponsor: Merrimack Pharmaceuticals
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Aug 2014 --> May 2016
- everolimus / Generic mfg.
Trial primary completion date, Metastases: Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors (clinicaltrials.gov) - Jun 11, 2015
P2, N=29, Recruiting, Sponsor: Hellenic Cooperative Oncology Group
Trial primary completion date: Aug 2014 --> May 2016 Trial primary completion date: Sep 2015 --> Dec 2015
- Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: TSAP: Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: May 2014 --> May 2016
- everolimus / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date, Metastases: Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=72, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: May 2014 --> May 2016 Trial primary completion date: Dec 2014 --> Aug 2014
- everolimus / Generic mfg.
Trial primary completion date: Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma (clinicaltrials.gov) - Jun 11, 2015
P2, N=60, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2014 --> Aug 2014 Trial primary completion date: Jan 2015 --> Jan 2016
- everolimus / Generic mfg.
Trial primary completion date: Everolimus in Treating Patients With Recurrent Low-Grade Glioma (clinicaltrials.gov) - Jun 11, 2015
P2, N=60, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- Avastin (bevacizumab) / Roche
Trial termination: Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma (clinicaltrials.gov) - Jun 11, 2015
P2, N=18, Terminated, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Dec 2014 --> Dec 2015 Completed --> Terminated; Study terminated early due to slow accrual
- ||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Enrollment change, Trial primary completion date: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Jun 11, 2015
P4, N=52, Recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; Study terminated early due to slow accrual N=31 --> 52 | Trial primary completion date: Jun 2022 --> Sep 2022
- Enrollment change, Trial termination, Trial primary completion date: The Everolimus-Transplant Exit Strategy Trial (E-TEST) (clinicaltrials.gov) - Jun 8, 2015
P3, N=1, Terminated, Sponsor: Ashtar Chami
N=31 --> 52 | Trial primary completion date: Jun 2022 --> Sep 2022 N=60 --> 1 | Suspended --> Terminated | Trial primary completion date: Jan 2016 --> May 2014; Feasibility
- Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (clinicaltrials.gov) - May 29, 2015
P2, N=37, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Enrollment closed, Trial primary completion date: Myfortic in High MELD Liver Transplantation (clinicaltrials.gov) - May 27, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: University of Colorado, Denver
N=60 --> 1 | Suspended --> Terminated | Trial primary completion date: Jan 2016 --> May 2014; Feasibility Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Jul 2015
- cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg.
Trial completion: Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A (clinicaltrials.gov) - May 27, 2015
P2, N=12, Completed, Sponsor: Carsten Heinz
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Jul 2015 Active, not recruiting --> Completed
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Combination therapy, Metastases: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 27, 2015
P1, N=12, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- everolimus / Generic mfg.
New P2 trial: A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD (clinicaltrials.gov) - May 22, 2015
P2, N=30, Recruiting, Sponsor: New York University School of Medicine
- letrozole / Generic mfg., everolimus / Generic mfg.
New trial, Metastases: Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls (clinicaltrials.gov) - May 21, 2015
P=N/A, N=50, Recruiting, Sponsor: Sinai Hospital of Baltimore
- ||||| anastrozole / Generic mfg., everolimus / Generic mfg., fulvestrant / Generic mfg.
Metastases: S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer (clinicaltrials.gov) - May 21, 2015
P3, N=825, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
New P2 trial: Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors (clinicaltrials.gov) - May 20, 2015
P2, N=25, Recruiting, Sponsor: Samsung Medical Center